about
Implementation of a 'care bundle' improves the management of patients admitted to hospital with decompensated cirrhosisThiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patientsChemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammationFatigue in primary sclerosing cholangitis is associated with sympathetic over-activity and increased cardiac output.Relapse after withdrawal from anti-TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta-analysis.A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis.αEβ7 Integrin Identifies Subsets of Pro-Inflammatory Colonic CD4+ T Lymphocytes in Ulcerative Colitis.Breast cancer metastasis: demonstration that FOXP3 regulates CXCR4 expression and the response to CXCL12.Association Between Response to Etrolizumab and Expression of Integrin αE and Granzyme A in Colon Biopsies of Patients With Ulcerative Colitis.Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at ADCY7.Anti-tissue transglutaminase antibodies in the follow-up of adult coeliac disease.Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease.Faecal calprotectin or lactoferrin can identify postoperative recurrence in Crohn's disease.Donor intravascular monocyte trafficking: a potential therapeutic target for primary graft dysfunction following lung transplantation?AlphaE Integrin Expression Is Increased in the Ileum Relative to the Colon and Unaffected by InflammationThe Impact of NOD2 Variants on Fecal Microbiota in Crohn’s Disease and Controls Without Gastrointestinal DiseaseManagement of Crohn's diseaseThe diagnosis of primary eosinophilic oesophagitis in adults: missed or misinterpreted?Rifaximin may have a dramatic effect on hepatic encephalopathyGut-Selective Integrin-Targeted Therapies for Inflammatory Bowel DiseaseBritish Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adultsBritish Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemicUsing faecal immunochemical test (FIT) undertaken in a national screening programme for large-scale gut microbiota analysisAdaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel
P50
Q33625935-99D8A6DF-F1D6-4C28-A48D-83974A7678D6Q34516280-D4DC7847-ADF5-4674-8033-B55A3224200DQ35849570-2D313BB2-3611-41D1-BCD4-0869F9F34A14Q36532545-752C4885-0C5A-4A42-9E7A-6A3BAF9C0757Q36692197-322EFBF1-DEEB-42E9-9729-08003219A106Q37166229-BBD5F9F8-983A-4A36-BE26-C83876B8C1D4Q38814438-542016B1-842A-408C-8040-BBED339FC7EEQ38990809-6134A018-7ACB-4FEF-98B3-8D632306989AQ40369374-AB9D983B-0B57-49AD-8581-E4329C18CDD2Q41951157-6D788CD2-DF1A-4D62-B7FD-678F9095236DQ42171047-BEF05F4F-1885-4001-BFA3-EB9D6D6848B6Q42324368-197CE28A-1198-4E5C-9A74-0F0D981B3F50Q47965260-3E5CA1CE-63CD-403C-A605-7393B86E1DF4Q49545740-0600C000-4EFB-4356-B893-E550E50E0583Q57100580-2EF1BBCC-7F89-436F-8DF1-EA471D4A0245Q59715333-497538D9-1C2B-4051-A9D6-DF53FFA14148Q83145768-471EFC62-9AAA-4CCE-9035-55156B1972EBQ84190037-EF17A3AB-AA51-4920-8B57-CEBA55E2741CQ85278404-6EFAE6C8-F9EA-43B5-83B4-8EDAAC77D8B2Q88692000-9FAEA0B4-2CAB-418F-8A99-0A3272682CD0Q90339285-C9CBEB02-55A1-4BD0-9D17-3DFC9F183303Q92024695-4133E4E3-C47F-45AB-B678-4A9F7295C76CQ95264254-D0F135D4-3147-4C31-BE12-21AFDE342C29Q96229326-2E5BE828-52F9-4023-A352-D0A0F82AFE72
P50
description
researcher ORCID ID = 0000-0002-7271-4956
@en
name
Christopher A Lamb
@ast
Christopher A Lamb
@en
Christopher A Lamb
@nl
type
label
Christopher A Lamb
@ast
Christopher A Lamb
@en
Christopher A Lamb
@nl
prefLabel
Christopher A Lamb
@ast
Christopher A Lamb
@en
Christopher A Lamb
@nl
P31
P496
0000-0002-7271-4956